Nothing Special   »   [go: up one dir, main page]

WO2008040155A8 - 口服重组幽门螺杆菌疫苗及其制备方法 - Google Patents

口服重组幽门螺杆菌疫苗及其制备方法 Download PDF

Info

Publication number
WO2008040155A8
WO2008040155A8 PCT/CN2007/002655 CN2007002655W WO2008040155A8 WO 2008040155 A8 WO2008040155 A8 WO 2008040155A8 CN 2007002655 W CN2007002655 W CN 2007002655W WO 2008040155 A8 WO2008040155 A8 WO 2008040155A8
Authority
WO
WIPO (PCT)
Prior art keywords
helicobacter pylori
subunit
preparing method
recombinant protein
pylori vaccine
Prior art date
Application number
PCT/CN2007/002655
Other languages
English (en)
French (fr)
Other versions
WO2008040155A1 (zh
Inventor
Quanming Zou
Wende Tong
Xuhu Mao
Gang Guo
Dongshui Lu
Chao Wu
Hao Zeng
Yichao Wang
Jun Yang
Weijun Zhang
Kaiyun Liu
Ping Luo
Original Assignee
Chongqing Kang Wei Biotechnolo
Quanming Zou
Wende Tong
Xuhu Mao
Gang Guo
Dongshui Lu
Chao Wu
Hao Zeng
Yichao Wang
Jun Yang
Weijun Zhang
Kaiyun Liu
Ping Luo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing Kang Wei Biotechnolo, Quanming Zou, Wende Tong, Xuhu Mao, Gang Guo, Dongshui Lu, Chao Wu, Hao Zeng, Yichao Wang, Jun Yang, Weijun Zhang, Kaiyun Liu, Ping Luo filed Critical Chongqing Kang Wei Biotechnolo
Priority to KR1020097006936A priority Critical patent/KR101100237B1/ko
Priority to AT07800872T priority patent/ATE510560T1/de
Priority to EP07800872A priority patent/EP2082750B1/en
Priority to US12/310,658 priority patent/US8900594B2/en
Priority to JP2009526999A priority patent/JP5327873B2/ja
Publication of WO2008040155A1 publication Critical patent/WO2008040155A1/zh
Publication of WO2008040155A8 publication Critical patent/WO2008040155A8/zh
Priority to HK10101022.8A priority patent/HK1137337A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PCT/CN2007/002655 2006-09-05 2007-09-05 口服重组幽门螺杆菌疫苗及其制备方法 WO2008040155A1 (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR1020097006936A KR101100237B1 (ko) 2006-09-05 2007-09-05 경구용 재조합 헬리코박터 파일로리 백신 및 그의 제조방법
AT07800872T ATE510560T1 (de) 2006-09-05 2007-09-05 Oraler rekombinanter helicobacter-pylori-impstoff und sein herstellungsverfahren
EP07800872A EP2082750B1 (en) 2006-09-05 2007-09-05 Oral recombinant helicobacter pylori vaccine and preparing method thereof
US12/310,658 US8900594B2 (en) 2006-09-05 2007-09-05 Oral recombinant Helicobacter pylori vaccine and preparing method thereof
JP2009526999A JP5327873B2 (ja) 2006-09-05 2007-09-05 リコンビナントヘリコバクターピロリの経口ワクチン及びその調製方法
HK10101022.8A HK1137337A1 (en) 2006-09-05 2010-01-29 Oral recombinant helicobacter pylori vaccine and preparing method thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200610095094.0 2006-09-05
CNB2006100950940A CN100460013C (zh) 2006-09-05 2006-09-05 口服重组幽门螺杆菌疫苗及其制备方法

Publications (2)

Publication Number Publication Date
WO2008040155A1 WO2008040155A1 (zh) 2008-04-10
WO2008040155A8 true WO2008040155A8 (zh) 2009-07-30

Family

ID=37857625

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/002655 WO2008040155A1 (zh) 2006-09-05 2007-09-05 口服重组幽门螺杆菌疫苗及其制备方法

Country Status (9)

Country Link
US (1) US8900594B2 (zh)
EP (1) EP2082750B1 (zh)
JP (1) JP5327873B2 (zh)
KR (1) KR101100237B1 (zh)
CN (1) CN100460013C (zh)
AT (1) ATE510560T1 (zh)
ES (1) ES2363875T3 (zh)
HK (1) HK1137337A1 (zh)
WO (1) WO2008040155A1 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103339250B (zh) * 2010-06-25 2016-04-13 翁德克控股有限公司 控制幽门螺杆菌感染的持续性的工具
JP2015500864A (ja) * 2011-12-23 2015-01-08 ノバルティス アーゲー 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対して免疫するための安定な組成物
KR20140143139A (ko) * 2012-03-08 2014-12-15 소니 주식회사 핵산 증폭 반응용 마이크로 칩의 제조 방법
PL218700B1 (pl) 2012-03-29 2015-01-30 Gdański Univ Medyczny Doustna szczepionka zawierająca przetrwalniki Bacillus subtilis oraz jej zastosowanie do immunizacji przeciwko Helicobacter pylori
EP2844301A2 (en) * 2012-05-04 2015-03-11 Ineb-instituto de Engenharia Biomédica Microspheres for treating helicobacter pylori infections
EP2906821A4 (en) * 2012-10-09 2015-10-28 Carlos Gabriel Oroza WIND TURBINE FOR INSTALLATION IN BUILDINGS
CN103990121B (zh) * 2013-12-06 2015-07-08 上海联合赛尔生物工程有限公司 抗原嵌合体、抗原组合物、疫苗及其制备方法和试剂盒
KR102309957B1 (ko) * 2015-01-09 2021-10-08 주식회사 엘지생활건강 캡슐화한 콘키올린을 함유한 화장료 조성물
WO2016178158A1 (en) * 2015-05-07 2016-11-10 Csir Method for encapsulating pharmaceutical actives
AU2016374289B2 (en) 2015-12-14 2023-08-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Helicobacter pylori vaccines
EP3272354A1 (en) 2016-07-20 2018-01-24 Technische Universität München Agents and methods for the prevention or treatment of h. pylori infections
CN107184967A (zh) * 2017-03-27 2017-09-22 广州市妇女儿童医疗中心 一种基于枯草芽孢载体的幽门螺杆菌口服疫苗
CN107298716A (zh) * 2017-07-21 2017-10-27 成都亿妙生物科技有限公司 一种重组幽门螺杆菌蛋白疫苗及其制备方法
CN109280669A (zh) * 2017-07-21 2019-01-29 刘开云 大肠杆菌不耐热肠毒素基因片段及其应用
CN110075290A (zh) * 2018-01-25 2019-08-02 吴夙钦 流感黏膜疫苗组合物及其制备方法与应用
CN113144182B (zh) * 2021-04-22 2023-03-10 成都欧林生物科技股份有限公司 一种幽门螺杆菌口服缓释疫苗及其制备与应用
CN113151334A (zh) * 2021-04-22 2021-07-23 成都亿妙生物科技有限公司 一种幽门螺杆菌LuxS六聚体重组蛋白的发酵和纯化工艺
CN118105473B (zh) * 2024-04-30 2024-08-16 成都欧林生物科技股份有限公司 一种预防或治疗Hp感染口服免疫原性组合物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837240A (en) * 1995-04-28 1998-11-17 Oravax-Merieux Co. Multimeric, recombinant urease vaccine
CZ342697A3 (cs) * 1995-04-28 1998-06-17 Oravax, Inc. Multimerní rekombinantní ureázová vakcina
CN1188416A (zh) * 1995-04-28 1998-07-22 奥拉瓦克斯有限公司 多体的重组尿素酶疫苗
CN1323222A (zh) * 1998-06-19 2001-11-21 梅里厄奥拉瓦克斯公司 Lt和ct以非肠道免疫法抗螺旋杆菌感染
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
JP2004522402A (ja) * 1999-06-02 2004-07-29 ジェネンテック・インコーポレーテッド 同一のものをコードする分泌及び膜貫通ポリペプチドと核酸
AU2001271268A1 (en) * 2000-05-19 2001-12-03 The Administrators Of The Tulane Educational Fund Hybrid lt-a/ct-b holotoxin for use as an adjuvant
JP2004528031A (ja) * 2001-03-14 2004-09-16 セントカー・インコーポレーテツド 慢性閉塞性肺疾患関連の免疫グロブリン由来タンパク質、組成物、方法および用途
EP1494651A4 (en) * 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIO-ACTIVE MATERIALS WITH LYOPHILIZED FOAM
ITMI20031617A1 (it) * 2003-08-06 2005-02-07 Fond Carlo E Dirce Callerio Onlus Microcapsule a doppio strato di polisaccaridi utilizzabili
KR100673872B1 (ko) * 2004-04-19 2007-01-25 학교법인 성균관대학 요로감염증의 예방 및 치료를 위한 재조합 디엔에이,플라스미드, 형질전환 미생물 및 경구용 백신 단백질
US20060141021A1 (en) * 2004-12-29 2006-06-29 Industrial Technology Research Polymeric microspheres and method for preparing the same
WO2007117339A2 (en) * 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli

Also Published As

Publication number Publication date
CN1927394A (zh) 2007-03-14
EP2082750A1 (en) 2009-07-29
US8900594B2 (en) 2014-12-02
KR101100237B1 (ko) 2011-12-28
EP2082750B1 (en) 2011-05-25
KR20090053849A (ko) 2009-05-27
JP2010502199A (ja) 2010-01-28
CN100460013C (zh) 2009-02-11
EP2082750A4 (en) 2010-05-26
HK1137337A1 (en) 2010-07-30
US20110171315A1 (en) 2011-07-14
ATE510560T1 (de) 2011-06-15
JP5327873B2 (ja) 2013-10-30
ES2363875T3 (es) 2011-08-18
WO2008040155A1 (zh) 2008-04-10

Similar Documents

Publication Publication Date Title
WO2008040155A8 (zh) 口服重组幽门螺杆菌疫苗及其制备方法
WO2002064162A3 (en) Vaccine for transcutaneous immunization
WO2003094960A3 (en) Mucosal combination vaccines for bacterial meningitis
WO2003065973A3 (en) Multivalent streptococcal vaccine compositions and methods for use
JP2008530245A5 (zh)
NZ597858A (en) Vaccines and compositions against streptococcus pneumoniae
WO2008057235A3 (en) Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
WO2006066214A3 (en) Use of flagellin in the immunotherapy of yersinia pestis
JP2009520758A5 (zh)
Deng et al. Nanoparticulated heat-stable (STa) and heat-labile B subunit (LTB) recombinant toxin improves vaccine protection against enterotoxigenic Escherichia coli challenge in mouse
WO2003048390A8 (en) A process for the preparation of a non-toxic anthrax vaccine
WO2005007074A3 (en) Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention
WO2004026903A3 (en) Live antenuated parasite vaccine
WO2006080842A3 (en) Oral vaccines for fish
WO2001040449A3 (en) Cloning of a gene encoding an amino acid racemase from trypanosoma cruzi, and uses thereof
Chen et al. Biotechnologies applied in biomedical vaccines
WO2005065382A8 (en) Polypeptides and immunogenic conjugates capable of inducing antibodies against pathogens, and uses thereof
AU2003278175A1 (en) Vaccines of enhanced immunogenicity, and methods for preparing such vaccines
RU2004129738A (ru) Бактериальные споры
WO2005048918A3 (en) Anthrax vaccine
WO2004041182A3 (en) M. haemolytica outer membrane protein plpe as a vaccine or vaccine component against shipping fever
WO2018159476A1 (ja) 多価ワクチン
WO2010115278A8 (en) Methods and compositions for treating and preventing shiga toxin-producing escherichia coli infection
WO2002103002A3 (fr) Gene associe a la virulence du parasite leishmania
WO2001005424A3 (en) Multi-component vaccine to protect against disease caused by haemophilus influenzae and moraxella catarrhalis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07800872

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2009526999

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 510/MUMNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007800872

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020097006936

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 12310658

Country of ref document: US